News

Back

FEBS Journal – Special Issue on Cancer Therapeutics

FEBS Journal – Special Issue on Cancer Therapeutics

Published 21.12.2021.

The FEBS Journal published a special issue dedicated to the cancer research problematic. In this Special Issue on Cancer Therapeutics, The FEBS Journal highlights the latest advances in cancer therapy through twelve review articles and an interview-based article. 

You can read more on the link “Special Issue on Cancer Therapeutics”.

List of published articles:

  1. Watson CJ (2021) The ever-expanding landscape of cancer therapeutic approaches. FEBS J. 288, 6082– 6086.
  2. Skourti E & Letai A (2021) In conversation with Tony Letai. FEBS J 288, 6087– 6093.
  3. van der Zanden SY, Qiao X & Neefjes J (2020) New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J 288, 6094– 6110.
  4. Ashe H, Krakowiak P, Hasterok S, Sleppy R, Roller DG & Gioeli D (2021) Role of the runt-related transcription factor (RUNX) family in prostate cancer. FEBS J 288, 6111– 6125.
  5. Chatwin HV, Cruz Cruz J & Green AL (2021) Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy. FEBS J 288, 6126– 6140.
  6. Dupont CA, Riegel K, Pompaiah M, Juhl H & Rajalingam K (2021) Druggable genome and precision medicine in cancer: current challenges. FEBS J 288, 6141– 6157.
  7. Robinson RA, McMurran C, McCully ML & Cole DK (2021) Engineering soluble T-cell receptors for therapy. FEBS J 288, 6158– 6172.
  8. Yan S & Wan G (2021) Tumor-associated macrophages in immunotherapy. FEBS J 288, 6173– 6185.
  9. Wu L, Lian W & Zhao L (2021) Calcium signaling in cancer progression and therapy. FEBS J 288, 6186– 6204.
  10. Läubli H, Kawanishi K, Vazhappilly CG, Matar R, Merheb M & Siddiqui SS (2021) Tools to study and target the Siglec–sialic acid axis in cancer. FEBS J 288, 6205– 6224.
  11. Wang JZ, Lin TE, Wang K, Zhu H, Conway RM, Madigan MC, Murray M, Cherepanoff S, Zhou F & Shu W (2021) Development of new therapeutic options for the treatment of uveal melanoma. FEBS J 288, 6225– 6248.
  12. Naro C, Bielli P & Sette C (2021) Oncogenic dysregulation of pre-mRNA processing by protein kinases: challenges and therapeutic opportunities. FEBS J 288, 6249– 6271.
  13. Kemler I, Karamched B, Neuhauser C & Dingli D (2021) Quantitative imaging and dynamics of tumor therapy with viruses. FEBS J 288, 6272– 6284.
  14. Damen MPF, van Rheenen J & Scheele CLGJ (2020) Targeting dormant tumor cells to prevent cancer recurrence. FEBS J 288, 6285– 6302.